Journal article · 2021 · Open access
EPA guidance on treatment of negative symptoms in schizophrenia
European Psychiatry, 64(1), e21 · Published 17 March 2021 · DOI 10.1192/j.eurpsy.2021.13
In brief
“EPA guidance on treatment of negative symptoms in schizophrenia” is a 2021 journal article by Silvana Galderisi and 12 co-authors, published in European Psychiatry. OpenAlex counts 226 citations as of 20 November 2026, which puts it in the top 2% of works published in 2021 by citations. It is open access under a CC BY licence: the full text is free to read at European Psychiatry.
- Citations
- 226
- Most cited in
- 2025 (54)
- Field-weighted impact
- 19.55
- References
- 96
- Authors
- 13
Abstract
Negative symptoms of schizophrenia remain a major therapeutic challenge. The progress in the conceptualization and assessment is not yet fully reflected by treatment research. Nevertheless, there is a growing evidence base regarding the effects of biological and psychosocial interventions on negative symptoms. The importance of the distinction between primary and secondary negative symptoms for treatment selection might seem evident, but the currently available evidence remains limited. Good clinical practice is recommended for the treatment of secondary negative symptoms. Antipsychotic treatment should be optimized to avoid secondary negative symptoms due to side effects and due to positive symptoms. For most available interventions, further evidence is needed to formulate sound recommendations for primary, persistent, or predominant negative symptoms.However, based on currently available evidence recommendations for the treatment of undifferentiated negative symptoms (including both primary and secondary negative symptoms) are provided. Although it has proven difficult to formulate an evidence-based recommendation for the choice of an antipsychotic, a switch to a second-generation antipsychotic should be considered for patients who are treated with a first-generation antipsychotic. Antidepressant add-on to antipsychotic treatment is an option. Social skills training is recommended as well as cognitive remediation for patients who also show cognitive impairment. Exercise interventions also have shown promise. Finally, access to treatment and to psychosocial rehabilitation should be ensured for patients with negative symptoms. Overall, there is definitive progress in the field, but further research is clearly needed to develop specific treatments for negative symptoms.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Galderisi, S., Kaiser, S., Bitter, I., Nordentoft, M., Mucci, A., Sabé, M., Giordano, G. M., Nielsen, M. Ø., Glenthøj, L. B., Pezzella, P., Falkai, P., Dollfus, S., & Gäebel, W. (2021). EPA guidance on treatment of negative symptoms in schizophrenia. European Psychiatry, 64(1), e21. https://doi.org/10.1192/j.eurpsy.2021.13
MLA 9
Galderisi, Silvana, et al. “EPA guidance on treatment of negative symptoms in schizophrenia.” European Psychiatry, vol. 64, no. 1, 2021, p. e21. https://doi.org/10.1192/j.eurpsy.2021.13.
Chicago
Galderisi, Silvana, Stefan Kaiser, István Bitter, Merete Nordentoft, Armida Mucci, Michel Sabé, Giulia Maria Giordano, et al. 2021. “EPA guidance on treatment of negative symptoms in schizophrenia.” European Psychiatry 64 (1): e21. https://doi.org/10.1192/j.eurpsy.2021.13.
Harvard
Galderisi, S. et al. (2021) ‘EPA guidance on treatment of negative symptoms in schizophrenia’, European Psychiatry, 64(1), p. e21. doi:10.1192/j.eurpsy.2021.13.
IEEE
S. Galderisi et al., “EPA guidance on treatment of negative symptoms in schizophrenia,” European Psychiatry, vol. 64, no. 1, p. e21, 2021, doi: 10.1192/j.eurpsy.2021.13.
BibTeX
@article{galderisi2021guidance,
title = {{EPA guidance on treatment of negative symptoms in schizophrenia}},
author = {Galderisi, Silvana and Kaiser, Stefan and Bitter, István and Nordentoft, Merete and Mucci, Armida and Sabé, Michel and Giordano, Giulia Maria and Nielsen, M. Ø. and Glenthøj, Louise Birkedal and Pezzella, Pasquale and Falkai, Peter and Dollfus, Sonia and Gäebel, Wolfgang},
journal = {European Psychiatry},
year = {2021},
volume = {64},
number = {1},
pages = {e21},
doi = {10.1192/j.eurpsy.2021.13},
url = {https://doi.org/10.1192/j.eurpsy.2021.13}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2021 | 8 | |
| 2022 | 36 | |
| 2023 | 37 | |
| 2024 | 52 | |
| 2025 | 54 | |
| 2026 | 38 |
Its field-weighted citation impact is 19.55: it has been cited 19.55 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- schizophrenia
- negative symptoms
- primary negative symptoms
- secondary negative symptoms
- antipsychotic drugs
- atypical antipsychotics
- typical antipsychotics
- social skills training
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Galderisi, S., Kaiser, S., Bitter, I., Nordentoft, M., Mucci, A., Sabé, M., Giordano, G. M., Nielsen, M. Ø., Glenthøj, L. B., Pezzella, P., Falkai, P., Dollfus, S., & Gäebel, W. (2021). EPA guidance on treatment of negative symptoms in schizophrenia. European Psychiatry, 64(1), e21. https://doi.org/10.1192/j.eurpsy.2021.13
How many times has this paper been cited?
226 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at European Psychiatry: sign in and open the PDF from this page.
Who wrote this paper?
Silvana Galderisi, Stefan Kaiser, István Bitter, Merete Nordentoft, Armida Mucci, Michel Sabé, Giulia Maria Giordano, M. Ø. Nielsen, Louise Birkedal Glenthøj, Pasquale Pezzella, Peter Falkai, Sonia Dollfus and 1 more.
What is the DOI of this paper?
10.1192/j.eurpsy.2021.13, permanently at https://doi.org/10.1192/j.eurpsy.2021.13. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.